Navigation Links
New therapy for HIV treatment
Date:7/29/2008

Millions of people world-wide who have contracted a highly resistant strain of the HIV virus could benefit from a new drug to treat the infection.

Research co-authored by the University of New South Wales' (UNSW) National Centre in HIV Epidemiology and Clinical Research (NCHECR) shows that the majority of patients who have not responded to traditional treatments have had good results from a new combination therapy.

The drug raltegravir is already available in Australia and was listed on the Pharmaceutical Benefits Scheme on July 1st, with clinical trials showing that it is safe, effective and with minimal side-effects when used with other anti-HIV medicines.

The study, which has been published in the New England Journal of Medicine, shows the raltegravir effectively lowers the amount of virus in the blood to undetectable levels in 62 percent of people taking it in combination with other anti-HIV medicines.

Only one in three people who received a placebo plus other anti-HIV medicines had the amount of virus in the blood reduced to similar levels.

"This is the first drug in a new class of antiretroviral drugs called integrase inhibitors," said UNSW Professor David Cooper AO, the Director of NCHECR .

"The drug has a different mechanism of action, is very potent, seems very safe and has helped patients who have a virus that is resistant to older drugs and classes," said Professor Cooper.

"It initially will be used in developed countries, but hopefully, it will be made available at cheaper prices for patients in developing countries who are facing the same problems," said Professor Cooper.

The results were based on analyses of viral load reductions and CD4 cell count increases. A high CD4 cell count is crucial for a healthy immune system.

Professor Cooper said the efficacy shown at 48 weeks of treatment was consistent with observations at 24 weeks, indicating that the drug in combination has a durable effect.

The study shows the drug is well-tolerated by patients. It showed that only 0.9 percent of those receiving raltegravir discontinued therapy due to side-effects including nausea and headaches.


'/>"/>

Contact: Susi Hamilton
susi.hamilton@unsw.edu.au
61-293-851-583
University of New South Wales
Source:Eurekalert

Related medicine news :

1. Gentiva Safe Strides(R) Home Balance Therapy Program is Reducing Risk of Dangerous Falls and Relieving Pain for Thousands of Older Americans
2. Erectile dysfunction drugs allowed more chemotherapy to reach brain tumors in laboratory study
3. CSHL scientists correlate enzyme expression levels with chemotherapy drug response
4. D-cycloserine may improve behavioral therapy treatment for anxiety
5. Tx Xchange Launches Web-Based Solution for Physical Therapy and Rehabilitation Providers to Address Demands of Healthcare Consumerism
6. LSUHSC study finds high-dose HBO2 therapy extends survival window after cardiopulmonary arrest
7. Treating rare breast cancer with radiation therapy may lower recurrence rate
8. Medicare Modernization Act not associated with major changes in access to chemotherapy
9. Hormone Therapy Shows Little Benefit Against Prostate Cancer
10. Study points to cocktail therapy for Alzheimers
11. Global Med Technologies(R) Announces U.S. Release of Proven Tissue and Cellular Therapy Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul Thomas; ... WHAT: , Medical doctors and PhD scientists will speak to the press on behalf ... in support of an independent vaccine safety commission. , WHERE: , Zenger Room, ...
(Date:3/28/2017)... Conn. (PRWEB) , ... March 28, 2017 , ... ... based in Wethersfield, Conn., has relocated its corporate headquarters to a new, more ... clients. , In October 2016, Qualidigm purchased a distressed office building in ...
(Date:3/28/2017)... ... ... The Executives, Staff & Clients of MGE: Management Experts joined forces with ... Campaign at their Semi-Annual Graduation and Fundraiser Event at MGE’s St. Petersburg Office. , ... 14 internationally in literacy. Statistically, a direct relation can be a found between illiteracy ...
(Date:3/28/2017)... Square, PA (PRWEB) , ... March 28, 2017 , ... ... online and across a variety of business channels. , While many results are ... of any public relations program. , When it comes to measurement, firms should ...
(Date:3/28/2017)... ... 28, 2017 , ... Thank you to all who attended Capio Partners Winter ... event was exclusive to providers and offered an opportunity to collaborate and network with ... Manchester Grand Hyatt where attendees gathered for a lively discussion on trends and issues ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... The global surgical sealants ... of USD 4.5 billion by 2025, according to a ... of injured tissues post operation is a major step ... in 3% to 15% of cases and are considered ... third of postoperative deaths in patients. Surgical sealants and ...
(Date:3/27/2017)... , March 27, 2017 ... better understand Bayer and its partnering interests and activities since ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ... data. The report will be delivered in PDF ...
(Date:3/27/2017)...  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the ... of common stock in an underwritten public offering under ... Securities and Exchange Commission (the "SEC"). The offering is ... be no assurance as to whether or when the ... size or terms of the offering. Cryoport also expects ...
Breaking Medicine Technology: